A Nationwide Study on Severe Respiratory Syncytial Virus Infection in Children with Pulmonary Hypoplasia, Airway Stenosis, Esophageal Atresia, Inborn Errors of Metabolism, and Neuromuscular Diseases

A Nationwide Study on Severe Respiratory Syncytial Virus Infection in Children with Pulmonary Hypoplasia, Airway Stenosis, Esophageal Atresia, Inborn Errors of Metabolism, and Neuromuscular Diseases - A Nationwide Survey of Respiratory Syncytial Virus Infection in Five Newly Approved Indication Disease Groups

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061307

Enrollment

2100

Registered

2026-06-01

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypoplasia, Airway Stenosis, Esophageal Atresia, Inborn Errors of Metabolism, and Neuromuscular Diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children who have medical records from April 2022 to March 2026 and were between 0 and 5 years old at any point during that period, and who have one of the following five categories of diseases: pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorders, and neuromuscular diseases.

Exclusion criteria

Exclusion criteria: Children aged 5 years or older with any of the following five categories of diseases: pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorders, and neuromuscular diseases.

Design outcomes

Primary

Measure	Time frame
Proportion of hospitalizations due to RSV infection among the five target disease groups before and after the indication expansion Before indication expansion: April 2022 to March 2024 After indication expansion: April 2024 to March 2026	—

Countries

Japan

Contacts

Public ContactMasaaki Mori

Institute of Science Tokyo Departnment of Lifelong Immunotherapy

mori.phv@tmd.ac.jp+81-3-5803-4677

Outcome results